Phosphoinositide 3-kinase (PI3K) inhibition has been clinically validated, resulting in FDA approved therapies for the hematologic malignancies and most recently breast cancer; molecular characterization efforts suggest PI3K inhibition may benefit a subset of SBA patients. Here, PIK3CA is linked to hematologic disorder.